Rani Therapeutics Holdings Inc Cl A (RANI) Stock Price, Quote & News

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 457 3700

Website: www.ranitherapeutics.com

Address:

2051 Ringwood Avenue, San Jose, United States

Golden_Bullys Dec. 4 at 10:15 PM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $RANI $M $HL $SLDP $ABBV "

1 · Reply

Mapagotrades Dec. 4 at 10:00 PM

$AIRE $LITM $PSTV $RANI amazing moves today mentioned many times these plays💰👌

0 · Reply

__GoldingSteers Dec. 4 at 9:01 PM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $RANI $REKR $RBOT $MSPR all

0 · Reply

wa7ermelon Dec. 4 at 7:44 PM

if $RANI can do 750% move on a$10M upfront licensing deal, what can $LEXX do with a $50-100m upfront deal with Novo or Eli Lilly?

0 · Reply

Mapagotrades Dec. 4 at 6:07 PM

$LITM $AIRE Volume flow! $PSTV On verge of breakout $RANI Great recovery from the low volume pullbacks!

0 · Reply

ALPiNE1337 Dec. 4 at 5:32 PM

$RANI it’s about time now

0 · Reply

wavw Dec. 4 at 4:12 PM

$RANI yesterday filing shows the previous dilution. So started falling. Not a fresh dilution

0 · Reply

MK10 Dec. 4 at 3:09 PM

$RANI Lately there has been some pretty sweet moves here! I'm looking for some support, and a steady climb in the near future:)

0 · Reply

wavw Dec. 4 at 12:50 PM

$RANI why falling

0 · Reply

Iightning Dec. 4 at 8:00 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RANI Contract: Dec 19 $1C Entry: 0.55 Exit: 0.72 Return: +31.31% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Nov 6, 2025, 4:30 PM EST - 4 weeks ago

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Oct 30, 2025, 8:00 AM EDT - 5 weeks ago

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Oct 23, 2025, 4:05 PM EDT - 6 weeks ago

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Oct 23, 2025, 4:01 PM EDT - 6 weeks ago

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 20, 2025, 2:20 PM EDT - 6 weeks ago

Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai

Oct 20, 2025, 9:42 AM EDT - 6 weeks ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC CRMD RAPT

Oct 17, 2025, 7:48 AM EDT - 6 weeks ago

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Oct 17, 2025, 7:31 AM EDT - 6 weeks ago

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 17, 2025, 7:30 AM EDT - 6 weeks ago

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Aug 7, 2025, 4:35 PM EDT - 4 months ago

Rani (RANI) Q2 Net Loss Improves 16%

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Jul 15, 2025, 9:00 AM EDT - 5 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Jul 14, 2025, 5:00 AM EDT - 5 months ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

May 19, 2025, 8:00 AM EDT - 7 months ago

Rani Therapeutics Announces Research Agreement with Chugai

May 13, 2025, 4:05 PM EDT - 7 months ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Mar 31, 2025, 7:15 PM EDT - 8 months ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:05 PM EDT - 8 months ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Mar 26, 2025, 4:05 PM EDT - 9 months ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Mar 25, 2025, 6:00 PM EDT - 9 months ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oct 8, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in September Investor Conferences

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in August Investor Conferences

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

May 14, 2024, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Participate in May Investor Conferences

May 9, 2024, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

May 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

Mar 20, 2024, 7:05 PM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Mar 15, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Dec 14, 2023, 8:00 AM EST - 2 years ago

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Nov 8, 2023, 4:05 PM EST - 2 years ago

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Oct 19, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Oct 12, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Sep 19, 2023, 6:36 AM EDT - 2 years ago

Rani Therapeutics: Excellent Technology But Major Risks Ahead

Sep 18, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Sep 7, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Aug 11, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Jun 21, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Jun 8, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

May 24, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

May 10, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

May 5, 2023, 5:33 PM EDT - 2 years ago

Rani Therapeutics: Novel Drug Delivery System, Under-Covered And Early Stage

Golden_Bullys Dec. 4 at 10:15 PM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $RANI $M $HL $SLDP $ABBV "

1 · Reply

Mapagotrades Dec. 4 at 10:00 PM

$AIRE $LITM $PSTV $RANI amazing moves today mentioned many times these plays💰👌

0 · Reply

__GoldingSteers Dec. 4 at 9:01 PM

SNSE will SQUEEZE DON'T OVERLOOK IT!! $RANI $REKR $RBOT $MSPR all

0 · Reply

wa7ermelon Dec. 4 at 7:44 PM

if $RANI can do 750% move on a$10M upfront licensing deal, what can $LEXX do with a $50-100m upfront deal with Novo or Eli Lilly?

0 · Reply

Mapagotrades Dec. 4 at 6:07 PM

$LITM $AIRE Volume flow! $PSTV On verge of breakout $RANI Great recovery from the low volume pullbacks!

0 · Reply

ALPiNE1337 Dec. 4 at 5:32 PM

$RANI it’s about time now

0 · Reply

wavw Dec. 4 at 4:12 PM

$RANI yesterday filing shows the previous dilution. So started falling. Not a fresh dilution

0 · Reply

MK10 Dec. 4 at 3:09 PM

$RANI Lately there has been some pretty sweet moves here! I'm looking for some support, and a steady climb in the near future:)

0 · Reply

wavw Dec. 4 at 12:50 PM

$RANI why falling

0 · Reply

Iightning Dec. 4 at 8:00 AM

1ightning® Premium Options Alert (Actionable) Ticker: $RANI Contract: Dec 19 $1C Entry: 0.55 Exit: 0.72 Return: +31.31% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Pinceconez_Tradings Dec. 4 at 2:13 AM

Banked up $8.4K profits on that run! Thank you! Made my whole month! Make sure you FOLLOW @ICEMAN_ALERTS below, Great trader!! He calls them early before anyone else. Love adding before the runs✅ Adding more $SLNH $RANI $PAVS $ONDS tomorrow

0 · Reply

Mapagotrades Dec. 3 at 10:48 PM

Thursday watchlist part2: $KALA $RANI $SGBX $SES

0 · Reply

Tooneyman Dec. 3 at 10:26 PM

$RANI

0 · Reply

Mapagotrades Dec. 3 at 9:48 PM

$RANI 😀🔥🍋❤️

0 · Reply

Fishbonee Dec. 3 at 9:12 PM

$RANI 📈

0 · Reply

Bakhm Dec. 3 at 8:05 PM

$RANI Right now we’re basically playing a pawn that can turn into a queen. For giants like Novo Nordisk, Eli Lilly, AbbVie, Amgen, Pfizer, and Johnson & Johnson, this technology is absolutely unwelcome. Their multi-billion injection markets depend on needles — and a capsule that replaces injections breaks their whole model

1 · Reply

AboveNBeyond Dec. 3 at 7:49 PM

$RANI Loading up when low is the way to go. The question is is the ready to head towards that $10+ target?

0 · Reply

TheInside2028 Dec. 3 at 7:34 PM

$RANI https://wsw.com/webcast/evercore52/rani/2355540

1 · Reply

TheInside2028 Dec. 3 at 7:29 PM

$RANI There has never been a more exciting time at Rani Therapeutics. We have successfully tested the RaniPill in humans, and we are working towards the ultimate goal of making the oral delivery of biologics a reality for millions of patients. We are growing rapidly and we are actively hiring

1 · Reply

Lagoule Dec. 3 at 7:27 PM

$RANI FTDS!

0 · Reply

SanJose2 Dec. 3 at 7:16 PM

$RANI

0 · Reply

StockForthePoor2R Dec. 3 at 6:50 PM

$UNH Going to the moon $RANI 🚀🚀 $BYND 🚀🚀🚀

0 · Reply

Market Cap	167.69M
Revenue (ttm)	1.03M
Net Income (ttm)	-30.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,914.56%
Debt to Equity Ratio	-1.88

Volume	3,580,206
Avg Vol	22,638,205
Day's Range	N/A - N/A
Shares Out	121.51M
Stochastic %K	55%
Beta	0.40
Analysts	Strong Sell
Price Target	$9.25